基质金属蛋白酶与降主动脉瘤：均等、差异与转变
Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch.
作者信息
Theruvath Tom P, Jones Jeffrey A, Ikonomidis John S
机构信息
Division of Cardiothoracic Surgery, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
出版信息
J Card Surg. 2012 Jan;27(1):81-90. doi: 10.1111/j.1540-8191.2011.01315.x. Epub 2011 Sep 29.
Abstract
Central to the pathologic changes in developing aortic aneurysms are alterations in the abundance and activity of proteases, of which the most important for aneurysm production comprise the matrix metalloproteinase (MMP) family. In this review, literature demonstrating the role of MMPs in the development of aortic aneurysms is presented, with emphasis on the parity and disparity between the thoracic and abdominal aorta. Furthermore, the role of embryologic cellular origins and evidence of phenotypic switch will be addressed in terms of how this process alters MMP production during aneurysm development.
摘要
发育性主动脉瘤病理变化的核心是蛋白酶的丰度和活性改变，其中对动脉瘤形成最重要的是基质金属蛋白酶（MMP）家族。在本综述中，将展示证明MMPs在主动脉瘤发展中作用的文献，重点关注胸主动脉和腹主动脉之间的异同。此外，将从胚胎细胞起源过程如何在动脉瘤发展过程中改变MMP产生的角度，探讨胚胎细胞起源的作用和表型转换的证据。
相似文献
1
Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch.
J Card Surg. 2012 Jan;27(1):81-90. doi: 10.1111/j.1540-8191.2011.01315.x. Epub 2011 Sep 29.
2
Angiotensin I Infusion Reveals Differential Effects of Angiotensin-Converting Enzyme in Aortic Resident Cells on Aneurysm Formation.
Circ J. 2020 Apr 24;84(5):825-829. doi: 10.1253/circj.CJ-19-0955. Epub 2020 Mar 31.
3
Expression of matrix metalloproteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology.
Hum Pathol. 2006 Aug;37(8):1076-84. doi: 10.1016/j.humpath.2006.03.017. Epub 2006 Jun 19.
4
Prevention of abdominal aortic aneurysm progression by targeted inhibition of matrix metalloproteinase activity with batimastat-loaded nanoparticles.
Circ Res. 2015 Nov 6;117(11):e80-9. doi: 10.1161/CIRCRESAHA.115.307207. Epub 2015 Oct 6.
5
[Morphogenesis of thoracic aorta aneurysms: investigation of matrix metalloproteinases and their tissue inhibitors].
Medicina (Kaunas). 2002;38(1):31-5.
6
Differential hypertensive protease expression in the thoracic versus abdominal aorta.
J Vasc Surg. 2017 Nov;66(5):1543-1552. doi: 10.1016/j.jvs.2016.07.120. Epub 2016 Dec 27.
7
A biologic basis for asymmetric growth in descending thoracic aortic aneurysms: a role for matrix metalloproteinase 9 and 2.
J Vasc Surg. 2006 Feb;43(2):342-8. doi: 10.1016/j.jvs.2005.10.013.
8
Matrix metalloproteinase expression in the ascending aorta and aortic valve.
Interact Cardiovasc Thorac Surg. 2008 Feb;7(1):37-40. doi: 10.1510/icvts.2007.163311. Epub 2007 Nov 19.
9
Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model.
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H114-24. doi: 10.1152/ajpheart.00028.2010. Epub 2010 Apr 23.
10
Regulation of membrane type-1 matrix metalloproteinase activity and intracellular localization in clinical thoracic aortic aneurysms.
J Thorac Cardiovasc Surg. 2017 Mar;153(3):537-546. doi: 10.1016/j.jtcvs.2016.10.065. Epub 2016 Nov 14.
引用本文的文献
1
New Directions in Diagnostics for Aortic Aneurysms: Biomarkers and Machine Learning.
J Clin Med. 2024 Jan 31;13(3):818. doi: 10.3390/jcm13030818.
2
The Role and Mechanism of SIRT6 in Regulating Phenotype Transformation of Vascular Smooth Muscle Cells in Abdominal Aortic Aneurysm.
Comput Math Methods Med. 2022 Jan 6;2022:3200798. doi: 10.1155/2022/3200798. eCollection 2022.
3
Gene Silencing for Elastic Matrix Regenerative Repair.
Tissue Eng Part A. 2022 Mar;28(5-6):239-253. doi: 10.1089/ten.TEA.2020.0221.
4
A validated mouse model capable of recapitulating the protective effects of female sex hormones on ascending aortic aneurysms and dissections (AADs).
Physiol Rep. 2020 Nov;8(22):e14631. doi: 10.14814/phy2.14631.
5
The genetics and biomechanics of thoracic aortic diseases.
Vasc Biol. 2019 Oct 15;1(1):R13-R25. doi: 10.1530/VB-19-0027. eCollection 2019.
6
Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm.
Am J Physiol Heart Circ Physiol. 2020 Mar 1;318(3):H652-H670. doi: 10.1152/ajpheart.00621.2019. Epub 2020 Feb 21.
7
Matrix Metalloproteinase in Abdominal Aortic Aneurysm and Aortic Dissection.
Pharmaceuticals (Basel). 2019 Aug 6;12(3):118. doi: 10.3390/ph12030118.
8
Mapping Semaphorins and Netrins in the Pathogenesis of Human Thoracic Aortic Aneurysms.
Int J Mol Sci. 2019 Apr 28;20(9):2100. doi: 10.3390/ijms20092100.
9
TLR4 and MMP2 polymorphisms and their associations with cardiovascular risk factors in susceptibility to aortic aneurysmal diseases.
Biosci Rep. 2019 Jan 8;39(1). doi: 10.1042/BSR20181591. Print 2019 Jan 31.
10
Phenotypic and Functional Changes of Endothelial and Smooth Muscle Cells in Thoracic Aortic Aneurysms.
Int J Vasc Med. 2016;2016:3107879. doi: 10.1155/2016/3107879. Epub 2016 Jan 19.
本文引用的文献
1
A randomized placebo controlled trial of the effect of preoperative statin use on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and peak wall stress in patients undergoing elective open repair of abdominal aortic aneurysm.
Ann Vasc Surg. 2011 Jan;25(1):32-8. doi: 10.1016/j.avsg.2010.06.006.
2
A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion.
J Vasc Surg. 2010 Dec;52(6):1675-81. doi: 10.1016/j.jvs.2010.04.082. Epub 2010 Jul 17.
3
Role of myofibroblasts in vascular remodelling: focus on restenosis and aneurysm.
Cardiovasc Res. 2010 Dec 1;88(3):395-405. doi: 10.1093/cvr/cvq224. Epub 2010 Jul 8.
4
Editorial comment: biomarkers for diagnosis in thoracic aortic disease.
Cardiol Clin. 2010 May;28(2):221-2. doi: 10.1016/j.ccl.2010.02.017.
5
Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model.
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H114-24. doi: 10.1152/ajpheart.00028.2010. Epub 2010 Apr 23.
6
Cellular phenotype transformation occurs during thoracic aortic aneurysm development.
J Thorac Cardiovasc Surg. 2010 Sep;140(3):653-9. doi: 10.1016/j.jtcvs.2009.12.033. Epub 2010 Mar 9.
7
Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling.
Am J Pathol. 2009 Oct;175(4):1746-56. doi: 10.2353/ajpath.2009.081141. Epub 2009 Sep 3.
8
Regional heterogeneity within the aorta: relevance to aneurysm disease.
J Thorac Cardiovasc Surg. 2008 Nov;136(5):1123-30. doi: 10.1016/j.jtcvs.2008.06.027. Epub 2008 Jul 24.
9
Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo.
J Biol Chem. 2009 Jan 16;284(3):1765-71. doi: 10.1074/jbc.M806239200. Epub 2008 Nov 14.
10
Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis.
J Vasc Res. 2009;46(2):119-37. doi: 10.1159/000151766. Epub 2008 Sep 2.
Zotero 插件